Therapeutic effects of alendronate 35 mg once weekly and 5 mg once daily in Japanese patients with osteoporosis: a double-blind, randomized study (Q46679560)

From Wikidata

Jump to navigation Jump to search

scientific article published in January 2005

Language	Label	Description	Also known as
English	Therapeutic effects of alendronate 35 mg once weekly and 5 mg once daily in Japanese patients with osteoporosis: a double-blind, randomized study	scientific article published in January 2005

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16133688

Therapeutic effects of alendronate 35 mg once weekly and 5 mg once daily in Japanese patients with osteoporosis: a double-blind, randomized study (English)

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16133688

0 references

13

object named as

Yasuo Ohashi

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16133688

author name string

Shinji Uchida

1

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16133688

Tadaaki Taniguchi

2

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16133688

Takafumi Shimizu

3

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16133688

Taro Kakikawa

4

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16133688

Kotoba Okuyama

5

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16133688

Masahiko Okaniwa

6

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16133688

Hironori Arizono

7

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16133688

Koichi Nagata

8

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16133688

Arthur C Santora

9

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16133688

Masataka Shiraki

10

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16133688

Masao Fukunaga

11

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16133688

Tatsushi Tomomitsu

12

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16133688

Toshitaka Nakamura

14

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16133688

publication date

1 January 2005

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16133688

Journal of Bone and Mineral Metabolism

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16133688

23

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16133688

5

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16133688

382-388

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16133688

Weekly administration of alendronate: rationale and plan for clinical assessment

1 reference

https://pubmed.ncbi.nlm.nih.gov/16133688

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study

1 reference

https://pubmed.ncbi.nlm.nih.gov/16133688

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/16133688

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Multinational, Placebo-Controlled, Randomized Trial of the Effects of Alendronate on Bone Density and Fracture Risk in Postmenopausal Women with Low Bone Mass: Results of the FOSIT Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/16133688

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/16133688

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/16133688

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/16133688

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The upper GI safety and tolerability of oral alendronate at a dose of 70 milligrams once weekly: a placebo-controlled endoscopy study

1 reference

https://pubmed.ncbi.nlm.nih.gov/16133688

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/16133688

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fracture prediction from bone mineral density in Japanese men and women

1 reference

https://pubmed.ncbi.nlm.nih.gov/16133688

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prevention of nonvertebral fractures by alendronate. A meta-analysis. Alendronate Osteoporosis Treatment Study Groups

1 reference

https://pubmed.ncbi.nlm.nih.gov/16133688

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Oral bisphosphonates and upper gastrointestinal tract problems: what is the evidence?

1 reference

https://pubmed.ncbi.nlm.nih.gov/16133688

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/16133688

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Putting evidence-based medicine into clinical practice: comparing anti-resorptive agents for the treatment of osteoporosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/16133688

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Alendronate: an update of its use in osteoporosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/16133688

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/16133688

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Overview of patient compliance with medication dosing: a literature review

1 reference

https://pubmed.ncbi.nlm.nih.gov/16133688

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Patients with osteoporosis prefer once weekly to once daily dosing with alendronate

1 reference

https://pubmed.ncbi.nlm.nih.gov/16133688

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/16133688

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A double-masked multicenter comparative study between alendronate and alfacalcidol in Japanese patients with osteoporosis. The Alendronate Phase III Osteoporosis Treatment Research Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/16133688

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/16133688

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Osteoporosis prevention, diagnosis, and therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/16133688

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tolerability of once-weekly alendronate in patients with osteoporosis: a randomized, double-blind, placebo-controlled study

1 reference

https://pubmed.ncbi.nlm.nih.gov/16133688

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/16133688

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ten years' experience with alendronate for osteoporosis in postmenopausal women

1 reference

https://pubmed.ncbi.nlm.nih.gov/16133688

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Alendronate reduced vertebral fracture risk in postmenopausal Japanese women with osteoporosis: a 3-year follow-up study

1 reference

https://pubmed.ncbi.nlm.nih.gov/16133688

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women

1 reference

https://pubmed.ncbi.nlm.nih.gov/16133688

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A placebo-controlled, single-blind study to determine the appropriate alendronate dosage in postmenopausal Japanese patients with osteoporosis. The Alendronate Research Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/16133688

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00774-005-0616-5

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16133688

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16133688

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46679560&oldid=2268376280"